{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:43:31Z","timestamp":1792122211442,"version":"4.4.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2804205"],"award-info":[{"award-number":["2022YFC2804205"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2804104"],"award-info":[{"award-number":["2022YFC2804104"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["42276137"],"award-info":[{"award-number":["42276137"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022963","name":"Key Research and Development Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2021C03084"],"award-info":[{"award-number":["2021C03084"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Candida auris is a widely distributed, highly lethal, multidrug-resistant fungal pathogen. It was first identified in 2009 when it was isolated from fluid drained from the external ear canal of a patient in Japan. Since then, it has caused infectious outbreaks in over 45 countries, with mortality rates approaching 60%. Drug resistance is common in this species, with a large proportion of isolates displaying fluconazole resistance and nearly half are resistant to two or more antifungal drugs. In this review, we describe the drug resistance mechanism of C. auris and potential small-molecule drugs for treating C. auris infection. Among these antifungal agents, rezafungin was approved by the US Food and Drug Administration (FDA) for the treatment of candidemia and invasive candidiasis on March 22, 2023. Ibrexafungerp and fosmanogepix have entered phase III clinical trials.<\/jats:p>","DOI":"10.1093\/mmy\/myad127","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T04:33:36Z","timestamp":1702096416000},"source":"Crossref","is-referenced-by-count":26,"title":["Review of treatment options for a multidrug-resistant fungus: <i>Candida auris<\/i>"],"prefix":"10.1093","volume":"62","author":[{"given":"Siqi","family":"Wang","sequence":"first","affiliation":[{"name":"College of Pharmaceutical Science, Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, and Zhejiang Provincial Key Laboratory of TCM for Innovative R&D and Digital Intelligent Manufacturing of TCM Great Health Products, Zhejiang University of Technology , Hangzhou , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangwei","family":"Pan","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Science, Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, and Zhejiang Provincial Key Laboratory of TCM for Innovative R&D and Digital Intelligent Manufacturing of TCM Great Health Products, Zhejiang University of Technology , Hangzhou , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Gu","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Science, Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, and Zhejiang Provincial Key Laboratory of TCM for Innovative R&D and Digital Intelligent Manufacturing of TCM Great Health Products, Zhejiang University of Technology , Hangzhou , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Science, Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, and Zhejiang Provincial Key Laboratory of TCM for Innovative R&D and Digital Intelligent Manufacturing of TCM Great Health Products, Zhejiang University of Technology , Hangzhou , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wei","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Science, Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, and Zhejiang Provincial Key Laboratory of TCM for Innovative R&D and Digital Intelligent Manufacturing of TCM Great Health Products, Zhejiang University of Technology , Hangzhou , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huawei","family":"Zhang","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Science, Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, and Zhejiang Provincial Key Laboratory of TCM for Innovative R&D and Digital Intelligent Manufacturing of TCM Great Health Products, Zhejiang University of Technology , Hangzhou , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5819-8441","authenticated-orcid":false,"given":"Jianwei","family":"Chen","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Science, Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, and Zhejiang Provincial Key Laboratory of TCM for Innovative R&D and Digital Intelligent Manufacturing of TCM Great Health Products, Zhejiang University of Technology , Hangzhou , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Science, Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, and Zhejiang Provincial Key Laboratory of TCM for Innovative R&D and Digital Intelligent Manufacturing of TCM Great Health Products, Zhejiang University of Technology , Hangzhou , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"2024011014310458100_bib1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/jof5030058","article-title":"On the origins of a species: what might explain the rise of Candida auris","volume":"5","author":"Jackson","year":"2019","journal-title":"J Fungi (Basel)"},{"key":"2024011014310458100_bib2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/jof5040111","article-title":"Candida auris: a review of recommendations for detection and control in healthcare settings","volume":"5","author":"Caceres","year":"2019","journal-title":"J Fungi (Basel)"},{"key":"2024011014310458100_bib3","first-page":"1276","article-title":"Candida auris: another frontier in the battle against antimicrobial resistance","volume":"381","author":"Tina","year":"2023","journal-title":"BMJ"},{"key":"2024011014310458100_bib4","first-page":"e00007","article-title":"Insights into the unique nature of the East Asian clade of the emerging pathogenic yeast Candida auris","volume":"57","author":"Rory","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2024011014310458100_bib5","article-title":"Fungal priority pathogen list to guide research, development and public health action","author":"WHO","year":"2022"},{"key":"2024011014310458100_bib6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7326\/M22-3469","article-title":"Worsening spread of Candida auris in the United States, 2019 to 2021","volume":"176","author":"Meghan","year":"2023","journal-title":"Ann Intern Med"},{"key":"2024011014310458100_bib7","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/antibiotics9090558","article-title":"Characteristics and management of Candidaemia episodes in an established Candida auris outbreak","volume":"9","author":"Mulet\u00a0Bayona","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2024011014310458100_bib8","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1007\/s00330-020-06860-3","article-title":"CT features of novel coronavirus pneumonia (COVID-19) in children","volume":"30","author":"Duan","year":"2020","journal-title":"Eur Radiol"},{"key":"2024011014310458100_bib9","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.3389\/fmicb.2018.03081","article-title":"Candida auris: what have we learned about its mechanisms of pathogenicity?","volume":"9","author":"Rossato","year":"2018","journal-title":"Front Microbiol"},{"key":"2024011014310458100_bib10","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/jac\/dkx480","article-title":"A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009\u201317) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance","volume":"73","author":"Anuradha","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024011014310458100_bib11","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/cid\/ciw691","article-title":"Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses","volume":"64","author":"Shawn","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024011014310458100_bib12","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3201\/eid2611.203504","article-title":"Multidrug-resistant Candida auris infections in critically ill coronavirus disease patients, India, April\u2013July 2020","volume":"26","author":"Chowdhary","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2024011014310458100_bib13","first-page":"00029","article-title":"Candida auris: a review of the literature","volume":"31","author":"Jeffery","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"2024011014310458100_bib14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13643-017-0644-y","article-title":"Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study","volume":"6","author":"Bramer","year":"2017","journal-title":"Syst Rev"},{"key":"2024011014310458100_bib15","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/jof9020168","article-title":"Functional expression of recombinant Candida auris proteins in Saccharomyces cerevisiae enables azole susceptibility evaluation and drug discovery","volume":"9","author":"Toepfer","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"2024011014310458100_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.fgb.2019.02.008","article-title":"Genotypic and phenotypic characterization of Candida albicans Lebanese hospital isolates resistant and sensitive to caspofungi","volume":"127","author":"Toutounji","year":"2019","journal-title":"Fungal Genet Biol"},{"key":"2024011014310458100_bib17","doi-asserted-by":"crossref","first-page":"001318","DOI":"10.1099\/jmm.0.001318","article-title":"On the emergence, spread and resistance of Candida auris: host, pathogen and environmental tipping points","volume":"70","author":"Chakrabarti","year":"2021","journal-title":"J Med Microbiol"},{"key":"2024011014310458100_bib18","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3389\/fcimb.2021.742062","article-title":"Application of machine learning classifier to Candida auris\u00a0drug resistance analysis","volume":"11","author":"Li","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"2024011014310458100_bib19","doi-asserted-by":"crossref","first-page":"\u00a0008","DOI":"10.1093\/mmy\/myac008","article-title":"Emerging and future strategies in the management of recalcitrant Candida auris","volume":"60","author":"Bandara","year":"2022","journal-title":"Med Mycol"},{"key":"2024011014310458100_bib20","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/jac\/dky153","article-title":"Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model","volume":"73","author":"Hager","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024011014310458100_bib21","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3390\/jof6040192","article-title":"Review of the novel echinocandin antifungal rezafungin: animal studies and clinical data","volume":"6","author":"Zhao","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2024011014310458100_bib22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jgar.2018.02.013","article-title":"Rezafungin (CD101), a next-generation echinocandin: a systematic literature review and assessment of possible place in therapy","volume":"14","author":"Sofjan","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"2024011014310458100_bib23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.micpath.2018.09.014","article-title":"Candida auris: epidemiology, risk factors, virulence, resistance, and therapeutic options","volume":"125","author":"Luiz","year":"2018","journal-title":"Microb Pathog"},{"key":"2024011014310458100_bib24","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/jac\/dkz390","article-title":"In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae","volume":"74","author":"T\u00f3th","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024011014310458100_bib25","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/mmy\/myz012","article-title":"Antifungal drugs: what brings the future?","volume":"57","author":"Van","year":"2019","journal-title":"Med Mycol"},{"key":"2024011014310458100_bib26","article-title":"Rezafungin for injection. FDA briefing document","author":"US Food and Drug Administration","year":"2023"},{"key":"2024011014310458100_bib27","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3390\/antibiotics9090539","article-title":"Ibrexafungerp: a novel oral triterpenoid antifungal in development for the treatment of Candida auris infections","volume":"9","author":"Ghannoum","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2024011014310458100_bib28","doi-asserted-by":"crossref","first-page":"e127661","DOI":"10.1016\/j.bmcl.2020.127661","article-title":"Ibrexafungerp: an orally active beta-1,3-glucan synthesis inhibitor","volume":"32","author":"Apgar","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"key":"2024011014310458100_bib29","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/mmy\/myz083","article-title":"Ibrexafungerp: a novel oral glucan synthase inhibitor","volume":"58","author":"Davis","year":"2020","journal-title":"Med Mycol"},{"key":"2024011014310458100_bib30","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"key":"2024011014310458100_bib31","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/ofid\/ofaa439.925","article-title":"Ibrexafungerp demonstrates potent and consistent in vitro activity against &gt;400 global Candida auris isolates, including isolates with elevated MIC's to echinocandins","volume":"7","author":"Katyna","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2024011014310458100_bib32","doi-asserted-by":"crossref","first-page":"e02694","DOI":"10.1128\/AAC.02694-20","article-title":"Ibrexafungerp demonstratesin vitroactivity against fluconazole-resistant Candida auris and in vivo efficacy with delayed initiation of therapy in an experimental model of invasive candidiasis","volume":"65","author":"Wiederhold","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2024011014310458100_bib33","doi-asserted-by":"crossref","first-page":"e00854","DOI":"10.1128\/AAC.00854-20","article-title":"Efficacy of ibrexafungerp (SCY-078) against Candida auris in an in vivo guinea pig cutaneous infection model","volume":"64","author":"Ghannoum","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2024011014310458100_bib34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/ofid\/ofx163.132","article-title":"VT-1598 inhibits the in vitro\u00a0growth of mucosal Candida isolates and protects against oropharyngeal candidiasis in IL-17 deficient mice","volume":"4","author":"Timothy","year":"2017","journal-title":"Open Forum Infec Dis"},{"key":"2024011014310458100_bib35","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ijantimicag.2017.09.002","article-title":"The antifungal arsenal: alternative drugs and future targets","volume":"51","author":"Nathan","year":"2018","journal-title":"Int J Antimicro Agents"},{"key":"2024011014310458100_bib36","doi-asserted-by":"crossref","first-page":"e02233","DOI":"10.1128\/AAC.02233-18","article-title":"The fungal CYP51-specific inhibitor VT-1598 demonstrates in vitro\u00a0and in vivo activity against Candida auris","volume":"63","author":"Wiederhold","year":"2019","journal-title":"Antimicro Agents Chemother"},{"key":"2024011014310458100_bib37","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1093\/jac\/dky242","article-title":"The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis","volume":"73","author":"Garvey","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024011014310458100_bib38","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/jof6040373","article-title":"PC945, a novel inhaled antifungal agent, for the treatment of respiratory fungal infections","volume":"6","author":"Murray","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2024011014310458100_bib39","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/jac\/dky170","article-title":"VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice","volume":"73","author":"Break","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024011014310458100_bib40","doi-asserted-by":"crossref","first-page":"e00690","DOI":"10.1002\/prp2.690","article-title":"Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent","volume":"9","author":"Cass","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"2024011014310458100_bib41","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1093\/jac\/dkz280","article-title":"In vitro antifungal activity of a novel topical triazole PC945 against emerging yeast Candida auris","volume":"74","author":"Rudramurthy","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024011014310458100_bib42","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/13543784.2020.1791819","article-title":"Innovative therapies for invasive fungal infections in preclinical and clinical development","volume":"29","author":"Yu","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"2024011014310458100_bib43","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/jac\/dkv398","article-title":"The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata","volume":"71","author":"Nathan","year":"2016","journal-title":"J Antimicro Chemother"},{"key":"2024011014310458100_bib44","doi-asserted-by":"crossref","first-page":"e02198","DOI":"10.1128\/AAC.02198-19","article-title":"The novel arylamidine T-2307 demonstrates in vitro\u00a0and in vivo activity against Candida auris","volume":"64","author":"Wiederhold","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2024011014310458100_bib45","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/ofid\/ofx163.1206","article-title":"Evaluation of the in vitro and in vivo antifungal activity of APX001A\/APX001 against Candida auris","volume":"4","author":"Emily","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2024011014310458100_bib46","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/jof6040239","article-title":"Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections","volume":"6","author":"Shaw","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2024011014310458100_bib47","doi-asserted-by":"crossref","first-page":"e01120","DOI":"10.1128\/AAC.01120-19","article-title":"Efficacy of delayed therapy with fosmanogepix (APX001) in a murine model of Candida auris invasive candidiasis","volume":"63","author":"Wiederhold","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024011014310458100_bib48","doi-asserted-by":"crossref","first-page":"e00523","DOI":"10.1128\/AAC.00523-18","article-title":"In vitro and in vivo evaluation of APX001A\/APX001 and other Gwt1 inhibitors against cryptococcus","volume":"62","author":"Shaw","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024011014310458100_bib49","first-page":"471","article-title":"In vitro and in vivo evaluation of the antifungal activity of APX001A\/APX001 against Candida auris","volume":"4","author":"Hager","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024011014310458100_bib50","first-page":"651","article-title":"In vitro activity of ravuconazole against Candida auris and vaginal candida isolates","volume":"24","author":"Jia","year":"2021","journal-title":"Mycoses"},{"key":"2024011014310458100_bib51","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/myc.13260","article-title":"In vitro activity of ravuconazole against Candida auris and vaginal candida isolates","volume":"64","author":"Dong","year":"2021","journal-title":"Mycoses"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mmy\/advance-article-pdf\/doi\/10.1093\/mmy\/myad127\/54143148\/myad127.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/62\/1\/myad127\/55367951\/myad127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/62\/1\/myad127\/55367951\/myad127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T14:50:12Z","timestamp":1704898212000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/doi\/10.1093\/mmy\/myad127\/7464055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,9]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myad127","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,12,8]]},"article-number":"myad127"}}